incidence ≥

Related by string. * incidences . Incidences . Incidence : colorectal cancer incidence . Colorectal cancer incidence . ERBITUX incidence . adverse reactions incidence . causality incidence . Cancer Incidence . Cancer Incidence Mortality . Breast Cancer Incidence . Incidence Study . Reduced Incidence / : BMI ≥ . adverse reactions ≥ . ≥ Grade . triglycerides ≥ . . aged ≥ * *

Related by context. Frequent words. (Click for all words.) 71 lymphopenia 70 discontinuations due 69 diarrhea nausea vomiting 69 leukopenia 69 treatment emergent adverse 68 laboratory abnormalities 68 nasopharyngitis 67 adverse reactions observed 67 arthralgia 67 peripheral edema 67 pruritis 67 febrile neutropenia 66 events AEs 66 stomatitis 66 hypomagnesemia 65 Neutropenia 65 asthenia 64 thromboembolic events 64 infusion reactions 64 Adverse events 64 myalgia 64 pyrexia 64 % CI #.#-#.# [007] 64 plus methotrexate 63 myelosuppression 63 plus gemcitabine 63 TYSABRI treated 62 chlorambucil 62 DOXIL 62 hypokalemia 62 renal toxicity 62 events SAEs 62 angioedema 62 endophthalmitis 62 achieved statistical significance 62 hypercalcemia 61 cerebrovascular events 61 mycophenolate mofetil 61 mg BID 61 pruritus 61 Adverse reactions 61 hepatotoxicity 61 thrombocytopenia 61 virologic response 61 CI -#.# 61 valacyclovir 61 thrombotic events 61 patients receiving ERBITUX 61 P = .# 60 COPD exacerbations 60 CI #.#-#.# [002] 60 AEs 60 tumor lysis syndrome 60 confidence interval #.#-#.# 60 neutropenia 60 inflammatory lesions 60 Navelbine 60 metastatic bone 60 hypoglycemic events 60 REMICADE ® 60 neuropsychiatric symptoms 59 mucositis 59 Lamictal XR 59 ARCALYST 59 hypersensitivity reactions 59 daunorubicin 59 plus dexamethasone 59 composite endpoint 59 bacteremia 59 mg QD 59 discontinuations 59 peginterferon alfa 2b 59 sulfasalazine 59 placebo p = 59 gastrointestinal GI 59 nausea headache 59 nausea fatigue 59 hypersensitivity reaction 59 PREZISTA r 59 renal insufficiency 58 systemic embolism 58 enalapril 58 myocardial infarction stroke 58 Secondary endpoints included 58 confidence interval CI 58 REVLIMID ® 58 ARICEPT 58 PEG Intron 58 LEXIVA 58 annualized relapse 58 asthma exacerbations 58 tolvaptan 58 seroprotection 58 % CI #.#-#.# [006] 58 duodenal ulcers 58 Urinary tract infections 58 cSSSI 58 secondary hyperparathyroidism 58 lacosamide 58 placebo controlled clinical trials 58 Thrombocytopenia

Back to home page